Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Apr;46(4):940-947.
doi: 10.1007/s00259-018-4143-8. Epub 2018 Sep 5.

Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response

Li Li  1   2 , Li Ma  2 , Dongping Shang  2 , Zhiguo Liu  2 , Qingxi Yu  2 , Suzhen Wang  2 , Xuepeng Teng  2 , Qiang Zhang  3 , Xudong Hu  2   4 , Wei Zhao  2 , Wenhong Hou  2 , Jianyue Jin  5 , Feng-Ming Spring Kong  6 , Jinming Yu  2 , Shuanghu Yuan  7   8
Affiliations
Clinical Trial

Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response

Li Li et al. Eur J Nucl Med Mol Imaging. 2019 Apr.

Abstract

Purpose: To explore the relationship between metabolic uptake of the 18F-ALF-NOTA-PRGD2 (18F-RGD) tracer on positron emission tomography/computerized tomography (PET/CT) and the antiangiogenic effect of apatinib in patients with solid malignancies.

Materials and patients: Patients with measurable lesions scheduled for second- or third-line single-agent therapy with apatinib were eligible for this prospective clinical trial. All patients underwent 18F-RGD PET/CT examination before the start of treatment. Standardized uptake values (SUVs) of contoured tumor lesions were computed and compared using independent sample t-tests or the Mann-Whitney U test. Receiver-operating characteristic (ROC) curve analysis was used to determine accuracy in predicting response. Survival curves were compared using the Kaplan-Meier method.

Results: Of 38 patients who consented to study participation, 25 patients with 42 measurable lesions met the criteria for inclusion in this response assessment analysis. The median follow-up time was 3 months (range, 1-10 months), and the median progression-free survival (PFS) was 3 months (95% confidence interval, 1.04-4.96). The SUVpeak and SUVmean were significantly higher in responding tumors than in non-responding tumors (4.98 ± 2.34 vs 3.59 ± 1.44, p = 0.048; 3.71 ± 1.15 vs 2.95 ± 0.49, P = 0.036). SUVmax did not differ between responding tumors and non-responding tumors (6.58 ± 3.33 vs 4.74 ± 1.83, P = 0.078). An exploratory ROC curve analysis indicated that SUVmean [area under the ROC curve (AUC) = 0.700] was a better parameter than SUVpeak (AUC = 0.689) for predicting response. Using a threshold value of 3.82, high SUVmean at baseline was associated with improved PFS (5.0 vs. 3.4 months, log-rank P = 0.036).

Conclusion: 18F-RGD uptake on PET/CT imaging pretreatment may predict the response to antiangiogenic therapy, with higher 18F-RGD uptake in tumors predicting a better response to apatinib therapy.

Keywords: 18F-RGD PET/CT; Antiangiogenic therapy; Integrin αvβ3; Malignancies.

PubMed Disclaimer

References

    1. J Cell Biol. 2001 Oct 29;155(3):459-70 - PubMed
    1. Science. 2002 Apr 5;296(5565):151-5 - PubMed
    1. Curr Drug Targets. 2003 Feb;4(2):123-31 - PubMed
    1. Nat Rev Cancer. 2002 Feb;2(2):83-90 - PubMed
    1. Semin Cancer Biol. 1992 Apr;3(2):65-71 - PubMed

Publication types

LinkOut - more resources